映恩生物登陆港交所首日大涨116.70%;百利天恒第10款ADC获批临床试验 | 医药早参

每日经济新闻
16 Apr

NO.1 映恩生物登陆港交所首日大涨116.70%  4月15日,映恩生物正式在港交所挂牌,截至收盘股价大涨116.70%。公司本次IPO(首次公开发行)认购募资总额为2.1亿美元,约合人民币15.4亿元,刷新了2022年以来港股18A生物科技公司的融资纪录。资料显示,映恩生物成立于2019年,主要研发创新抗体偶联药物(ADC),用于治疗癌症、自身免疫性疾病等。目前,公司已经打造了一条包括十多款...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10